Search Videos by Topic or Participant
Browse by Series:

Maintenance Therapy in Chronic Lymphocytic Leukemia

Panelists: Myron S. Czuczman, MD, Roswell Park; John C. Byrd, MD, Ohio State;Richard Furman, MD, Weill Cornell; Thomas J. Kipps, MD, UCSD; Shuo
Published: Saturday, Feb 21, 2015
For High-Definition, Click
Maintenance therapy has demonstrated some utility as a treatment for patients with chronic lymphocytic leukemia (CLL); however, its true benefit remains debatable. In two studies of CD20 monoclonal antibodies presented at the ASH Annual Meeting, an improvement in PFS was seen but not overall survival, when maintenance was compared with observation. However, efficacy benefits were offset by the adverse events experienced by patients on the maintenance treatments. 

Maintenance therapy could be used in patients who have only a partial response and tend to have a higher risk of progression, suggests Shou Ma, MD, PhD. It might be appropriate to wait and see if patients need therapy, since responses can be seen in the bone marrow 6 months after stopping frontline treatment, Thomas J. Kipps, MD, explains. 

Caution should be exercised when integrating maintenance rituximab or ofatumumab after frontline therapy, Myron Czuczman, MD, recommends. More data and follow-up is necessary before these maintenance strategies become a standard practice.
 


Slider Left
Slider Right
For High-Definition, Click
Maintenance therapy has demonstrated some utility as a treatment for patients with chronic lymphocytic leukemia (CLL); however, its true benefit remains debatable. In two studies of CD20 monoclonal antibodies presented at the ASH Annual Meeting, an improvement in PFS was seen but not overall survival, when maintenance was compared with observation. However, efficacy benefits were offset by the adverse events experienced by patients on the maintenance treatments. 

Maintenance therapy could be used in patients who have only a partial response and tend to have a higher risk of progression, suggests Shou Ma, MD, PhD. It might be appropriate to wait and see if patients need therapy, since responses can be seen in the bone marrow 6 months after stopping frontline treatment, Thomas J. Kipps, MD, explains. 

Caution should be exercised when integrating maintenance rituximab or ofatumumab after frontline therapy, Myron Czuczman, MD, recommends. More data and follow-up is necessary before these maintenance strategies become a standard practice.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x